Gilead draws harsh reviews as PhIII for $21B Immunomedics drug underwhelms Wall Street
Back in the summer of 2020, Gilead acquired Immunomedics for $21 billion hoping to turn its breast cancer drug Trodelvy into a megablockbuster. On Monday morning, however, Gilead got some news that it won’t be a slam dunk.
The big biotech revealed Trodelvy met its primary endpoint of progression-free survival in a Phase III study Monday, testing the drug in late-line metastatic HR+/HER2- breast cancer. But at the interim analysis, analysts and observers were left questioning just how big the benefit was, as Gilead did not release any hard data.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.